CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −421 | $326.81 | $138K | 26,053 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −353 | $327.67 | $116K | 25,700 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −107 | $328.71 | $35K | 25,593 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −182 | $329.71 | $60K | 25,411 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −87 | $330.85 | $29K | 25,324 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −101 | $331.93 | $34K | 25,223 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −42 | $332.64 | $14K | 25,181 |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Grant or award · Stock Option (right to buy) 10b5-1 | +10,480 | 10,480 | ||
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award 10b5-1 | +3,688 | 25,110 | ||
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −47 | $323.62 | $15K | 25,063 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −90 | $324.65 | $29K | 24,973 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −258 | $325.63 | $84K | 24,715 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −392 | $326.81 | $128K | 24,323 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −329 | $327.67 | $108K | 23,994 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −100 | $328.71 | $33K | 23,894 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −170 | $329.71 | $56K | 23,724 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −81 | $330.85 | $27K | 23,643 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −94 | $331.93 | $31K | 23,549 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −37 | $332.64 | $12K | 23,512 |
| 2026-03-02 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award · Stock Option (right to buy) 10b5-1 | +8,105 | 8,105 |
Page 7 of 41 · 816 trades